Since CM is a largely immune-mediated disease, PKCθ has previously been proposed as a promising therapeutic target to downregulate brain inflammation by abrogating the exuberant CD8+ T cell-mediated cytotoxicity and subsequent BBB breakdown. This evidence concerns the gene CD8A and inflammation.